FDA Promotional Review · OPDP Context
An AI assist can help with FDA promotional review — but only as a flagging layer, never as the decision-maker. FDA's Office of Prescription Drug Promotion (OPDP) enforces the rules on prescription drug promotion; the regulatory judgment stays with your reviewers. Hyfstele's assist surfaces candidate issues in a promotional piece for the Medical, Legal, and Regulatory team to rule on. It flags. You decide. No LLM sits inside the flag decision plane, and every call is anchored to a signed, tamper-evident record. See it working at mlr.hyfstele.com.
In the United States, prescription drug promotion is regulated. FDA's Office of Prescription Drug Promotion (OPDP), within the Center for Drug Evaluation and Research, reviews advertising and promotional labeling to ensure it is truthful, not misleading, fairly balanced between benefit and risk, and consistent with the FDA-approved labeling. When promotion falls short, OPDP can issue untitled or warning letters — a public, expensive outcome that a company would much rather avoid.
To stay ahead of that standard, pharmaceutical companies run every promotional piece — a detail aid, a website, a banner, an email, a social post — through internal MLR review: Medical, Legal, and Regulatory reviewers who check each claim against its reference, confirm fair balance and required risk information, and catch anything that reads as off-label. MLR is the company's own line of defense for the rules OPDP enforces.
This is where an AI assist earns its place: it can read the piece and its annotated references and quickly surface candidate issues — a claim that outruns its citation, a missing or stale reference, an omitted fair-balance statement, an implied indication the label does not support. It shortens the reviewer's search. It does not, and must not, make the regulatory call.
It flags. You decide.
Flag → Judge → Prove. There is no LLM inside the flag decision plane.
This is the load-bearing distinction for anyone doing FDA promotional review. An assist that decides whether a piece is compliant is a liability: the regulatory judgment is a human act with an accountable name attached to it, and OPDP holds the company responsible for it. An assist that flags candidate issues for a qualified reviewer to judge is exactly what a well-run MLR process needs — faster first passes, nothing missed, and the decision authority firmly with people.
Hyfstele is built around that line. The model runs in three stages, and it is deliberately confined to the first one:
The model reads the piece and its references and proposes candidate issues, each with the passage and citation attached.
A Medical, Legal, or Regulatory reviewer rules on each flag. This is the regulatory call — always a human, never the model.
The flag and the reviewer's decision are anchored to a signed, tamper-evident audit chain you can verify.
Because model output feeds a reviewer queue rather than a decision gate, a generation can never become an approval on its own. Be skeptical of any tool marketing "automated approval," "auto-clear," or "the AI signs off" on promotional material — in an OPDP context that is selling you regulatory risk, not throughput.
"No LLM in the flag decision plane" is a stronger statement than "a human reviews the output." It means the decision surface itself — the point where a flag is accepted, dismissed, or escalated, and where an approval is recorded — contains no model. The LLM's role ends when it hands a candidate issue to the queue. Everything downstream that carries regulatory weight is deterministic and human-driven.
Why this matters for FDA promotional review: it removes any path by which a model's probabilistic output could silently constitute a compliance determination. The record can always answer "who decided this, and on what basis" with a person, not a prompt. That is the difference between a tool that assists a regulated decision and a tool that quietly makes one.
A promotional decision is only as defensible as the record behind it. If a piece is later questioned — in an internal audit, a due-diligence review, or an OPDP inquiry — "we're confident the reviewer checked that" is not evidence. A signed audit chain is.
In Hyfstele, every inference call is anchored to a tamper-evident audit chain signed with post-quantum cryptography (ML-DSA). That yields a time-ordered, attributable, non-repudiable record of every issue the assist flagged and every decision the reviewer made. Because the chain is tamper-evident and signed, an entry cannot be quietly altered or backdated without breaking the signature. You are not reconstructing the review after the fact from logs you hope are complete — you are producing cryptographic evidence that it happened, exactly as recorded.
21 CFR Part 11 governs electronic records and electronic signatures in FDA-regulated settings, and GxP practice more broadly turns on data integrity — records that are attributable, legible, contemporaneous, original, and accurate. An AI layer touching promotional and clinical claims has to live up to the same expectations as any other regulated system.
A signed, tamper-evident audit chain maps directly onto those expectations for the AI assist: each entry is attributable (to a call and a reviewer), contemporaneous (time-ordered at the moment of the call), and protected against undetected change (the signature breaks if the record is altered). Combined with a deployment that keeps unreleased material inside your perimeter, it gives an MLR program an AI layer it can actually stand behind in front of an auditor — with model provenance and data residency accounted for rather than assumed.
The AI in FDA promotional review is a model you did not train, running somewhere, reading your unreleased promotional and clinical claims. The right questions are not only "is it accurate" but "can I prove what it did, and can it leak." Hyfstele makes four controls independently verifiable on your own hardware:
The weights running on your box are proven byte-identical to the public open-weight artifact. You verify the model is the model you think it is.
Dormant and latent capacity is enumerated, not hand-waved. You get an accounting of what the model can do, on the record.
No route to the internet and no name to resolve. Things go in, nothing comes out. Your unreleased claims never leave your perimeter.
Every inference call is anchored to a tamper-evident audit chain signed with post-quantum cryptography (ML-DSA). Attributable and non-repudiable.
Turn these into a vendor scorecard and make each one a demonstration, not a claim:
Hyfstele's pharmaceutical MLR promotional-review assist is running live. The demo walks the full Flag → Judge → Prove loop: the model flags candidate issues in a promotional piece, a reviewer judges them, and each step is proven against the signed audit chain. It is the fastest way to see exactly where the AI sits — and where it does not.
Open the live MLR demo, or talk to us about a deployment air-gapped inside your own environment.
Open the live demo Talk to usAI can assist FDA promotional review, but only as a flagging layer — not as the decision-maker. FDA's Office of Prescription Drug Promotion (OPDP) enforces the rules on prescription drug promotion under the FD&C Act and 21 CFR, and the regulatory judgment about whether a piece is compliant belongs to accountable humans. Hyfstele's assist surfaces candidate issues — unsupported efficacy claims, missing or inadequate fair balance, omitted risk information, off-label implications — for the Medical, Legal, and Regulatory reviewers to judge. The doctrine is "It flags. You decide."
OPDP is FDA's Office of Prescription Drug Promotion, the office within CDER that reviews prescription drug advertising and promotional labeling for truthfulness, fair balance, and consistency with the approved labeling. MLR (Medical, Legal, Regulatory) review is the internal process pharma companies run before material ships, precisely to meet the standards OPDP enforces. An AI assist speeds the internal MLR pass; it does not replace OPDP's authority or the reviewer's judgment.
No. There is no LLM inside the flag decision plane. The model runs only in the Flag stage, proposing candidate issues with the passage and reference attached. A human reviewer performs the Judge stage and makes every regulatory call. Because model output feeds a reviewer queue rather than a decision gate, a generation can never by itself constitute an approval or a compliance determination.
Every inference call is anchored to a tamper-evident audit chain signed with post-quantum cryptography (ML-DSA). That produces a time-ordered, attributable, non-repudiable record of what the assist flagged and what the reviewer decided. If a promotional decision is later questioned — internally, in an audit, or in an OPDP inquiry — you can produce cryptographic evidence of the review rather than reconstructing it from logs you hope are complete.
A live demo of the pharmaceutical MLR promotional-review assist is at mlr.hyfstele.com. It walks the full Flag, Judge, Prove workflow: the model flags candidate issues in a promotional piece, a reviewer judges them, and each step is proven against a signed audit chain.